Edwards

Edwards Lifesciences to Sell Critical Care to BD

Edwards will use the after-tax cash proceeds to fund strategic growth investments. The sale enhances Edwards'' balance sheet flexibility for disciplined investments in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heart failure.

Edwards'' SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued

LONDON--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve.

Edwards Lifesciences Expands Structural Heart Portfolio With

As the pioneer in valve innovation for more than 60 years, Edwards believes it is uniquely positioned to lead this next frontier of aortic valve disease treatment. Edwards anticipates FDA approval of the JenaValve Trilogy Heart Valve System in late 2025, which will represent the first approved therapy for patients suffering from AR.

Careers | Edwards Lifesciences

With more than 16,000 employees across the globe, we celebrate our inclusive culture and embrace the diverse perspectives and experiences of our Edwards team. No matter your position or location, you will impact the future of our breakthrough medical technologies and industry.

Newsroom

Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to

Who We Are